相关实验视频
Updated: Jul 19, 2025

07:09
The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
Published on: July 16, 2014
48.3K
塞布拉诺帕多尔用于治疗慢性疼痛
Amber N Edinoff1,2, Chelsi J Flanagan3, Logan T Roberts4
1Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Fruit St, Boston, MA, 02114, USA. aedinoff@mgh.harvard.edu.
Current pain and headache reports
|August 9, 2023
概括
塞布拉诺帕多尔是一种新型口服止痛药,显示出作为治疗慢性疼痛的阿片类药物的有效替代品的希望. 它提供了可比的疼痛缓解与潜在的滥用和成的风险较低.
科学领域:
- 药理学 药理学是指药理学的学科.
- 疼痛管理 疼痛管理
- 神经科学是一个神经科学.
背景情况:
- 慢性疼痛显著影响患者的福祉,影响身体,心理和社会功能.
- 阿片类药物是急性疼痛的标准,但需要替代方法来治疗慢性疼痛.
- 塞布拉诺帕多尔是一种新型的口服止痛药,作用于mu和诺西西类阿片类 (NOP) 受体.
研究的目的:
- 审查塞布拉诺帕多尔在疼痛管理中的潜在用途.
- 评估塞布拉诺帕多尔作为传统阿片类止痛药的替代品.
主要方法:
- 关于塞布拉诺帕多尔的临床前和临床研究的叙述性综述.
- 与安慰剂,吗啡和水利吗啡相比,对疗效和安全性数据的分析.
主要成果:
- 临床前研究表明,塞布拉诺帕多尔的疗效与吗啡相当.
- 临床试验表明,塞布拉诺帕多尔在减轻疼痛方面优于安慰剂和吗啡.
- 塞布拉诺帕多尔的滥用潜力比摩尼低.
结论:
- 塞布拉诺帕多尔是治疗慢性中度至重度疼痛的有希望的替代品.
- 与阿片类药物相比,它在镇痛方面提供了潜在的好处,并降低了成风险.
- 需要进一步的研究,以充分确定其安全性和有效性.
相关概念视频
Opioid Analgesics: Synthetic and Semisynthetic Opioids
335
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
335
Analgesia and Pain Management
657
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
657
Drugs for Treatment of Diarrhea-Predominant IBS
213
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
213
Opioid Analgesics: Morphine and Other Natural Cogeners
291
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
291
Drugs for Treatment of Constipation-Predominant IBS
210
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
210
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
173
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
173

